The Evolution of Advanced Renal Cell Carcinoma
Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.
Stay updated with breaking news from Clear Cell Rcc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brian Rini, MD, and Hans Hammers, MD, PhD, discuss the evolution of management for advanced renal cell carcinoma (RCC), noting the role of biomarkers and its use in practice.
Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.
“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.
The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.
The panel discusses the best approaches to treating patients with non-clear cell RCC.